 BOSTON, Jan. 04, 2022 GLOBE NEWSWIRE -- Yumanity Therapeutics NASDAQ: YMTX, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022. 